# Edwards Lifesciences Corporation (EW) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Technology. Price $89.90, market value $51.8 billion.

## Valuation
- **P/E (trailing): 53.5×** (5-yr avg 35.1×, 3-yr avg 30.1×). Edwards Lifesciences Corporation trades at 53.5× trailing earnings, well above its own five-year average of 35.1×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 26.6×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 8.0×**. Each dollar of revenue is priced at 8.0×.
- **Price / book: 4.9×**. The shares trade at 4.9× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 30.6×**. Enterprise value is 30.6× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.8%** (5-yr avg 1.7%). Free cash flow equals 2.8% of the market value, above its five-year average of 1.7%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 1.9%**. The inverse of the P/E: 1.9% of the price is earned each year.

## Profitability
- **Gross margin: 77.8%**. Edwards Lifesciences Corporation keeps 77.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 22.3%**. 22.3% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 17.7%**. 17.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 10.4%**. 10.4% on shareholders' equity is solid.
- **Return on invested capital: 14.3%**. Return on all capital, debt included, is 14.3%.
- **Return on assets: 7.3%**. Each dollar of assets produces 7.3% of profit.

## Growth
- **Revenue growth (1 yr): 11.5%** (3-yr 10.8%/yr, 5-yr 6.7%/yr). Revenue grew 11.5% over the last year, against 6.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -73.7%** (3-yr -9.1%/yr, 5-yr 7.1%/yr). Earnings per share fell 73.7%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 11.1%/yr**. Free cash flow has compounded at 11.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.06**. Debt is 0.06 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Edwards Lifesciences Corporation holds more cash than debt.
- **Altman Z-score: 11.06**. A Z-score of 11.06 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Edwards Lifesciences Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (26 analysts). 26 analysts cover Edwards Lifesciences Corporation; the consensus is buy, with an average price target of $100.96 (+12% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 11.0%** (YTD 5.5%, 3-mo 4.6%). The shares are up 11.0% over twelve months including dividends.
- **From 52-week high: -6.6%** (24.3% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 49**. An RSI of 49 is neutral.
- **Beta (1 yr): 0.55** (volatility 25%). Beta of 0.55 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EW · Page: https://foliofundamentals.com/stocks/ew

Not investment advice.